Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Overview
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Cotinga Pharmaceuticals Inc
Laek Therapeutics Shanghai Co Ltd
Merck & Co Inc
Novartis AG
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Dormant Products
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by ArQule Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Cotinga Pharmaceuticals Inc, H1 2020
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020